2025. Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study. Journal of Kidney Cancer. 12, 4 (Oct. 2025), 7–18. DOI:https://doi.org/10.15586/jkcvhl.v12i4.403.